Human Para, in conjunction with the Keating Family Foundation, is proud to announce their commitment to support a new research partnership between Johns Hopkins Medicine and Otakaro Pathways.

Published research has demonstrated that MAP is capable of adapting to an anaerobic (non-oxygen) state, rendering antibiotics with inhibitory activity under aerobic (oxygen) conditions ineffective. This differing susceptibility to antibiotics under aerobic vs. anaerobic conditions has significant implications for our understanding of the pathogenesis of MAP in vivo and the treatment of Crohn’s disease if MAP is established as a causative agent.

This study will seek to expand on previous work by focusing on a larger number of human MAP strains, which have been shown to have variable susceptibility patterns to antibiotics in vitro. Goals will include determining the optimum antibiotic combination(s) in vitro resulting in the most potent bactericidal activity against both aerobically growing and anaerobically adapted organisms. Testing will not only include a wide array of antibiotics based on previous and ongoing studies but also naturally occurring compounds and selected essential oils.

This study will commence January 2021, and the estimated cost will be $33,000 to support a research technologist and laboratory supplies.

Please help Human Para fund this and other innovative MAP research by making a donation today!